Article

DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTS

2022-06-24

Abstract excerpt

As the coronavirus SARS-CoV-2 continues to mutate into Variants of Concern (VOC), there is a growing and urgent need to develop effective antivirals to combat the newly emerged infectious disease COVID-19. Recent data indicate that monoclonal antibodies developed early in the pandemic are no longer capable of effectively neutralizing currently active VOCs. This report describes the design of a class of variant-agn...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 59133a87-24bf-5a7a-9dbc-e24a2b66ade7
DOI: 10.1101/2022.06.23.497326

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTSDOI 10.1101/2022.06.23.497326Read

Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion proteinSemantic proximity Read

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitorsSemantic proximity Read

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.Semantic proximity Read

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variantsSemantic proximity Read

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read

Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion proteinSemantic proximity Read

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitorsSemantic proximity Read

ACE2-based decoy receptors for SARS coronavirus 2.Semantic proximity Read